Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers successfully inhibit spread of cancer in mice


Many types of cancer--like those of the breast and prostate--would not be nearly as deadly if it weren’t for their ability to spread to vital organs. Still, scientists don’t yet fully understand the way in which cancer spreads, or metastasizes, or how to prevent the process.

Now, researchers at the San Francisco VA Medical Center (SFVAMC) have used a modified version of a naturally occurring human protein to decrease the spread of human breast cancer implanted in mice.

"We were able to significantly reduce the spread of the disease and decrease tumor growth without any evidence of toxicity," said senior author Gary Jarvis, PhD, a SFVAMC microbiologist and UCSF associate professor of laboratory medicine.

The current findings appear in the June issue of Clinical Cancer Research, with figures from the paper appearing on its cover.

Jarvis credits first author Constance John, PhD, a research chemist in his lab at the time, with coming up with the idea of interfering with the ability of cancer cells to stick to one another as a way of attacking metastasis. The ability to adhere to other cells is what allows a cell that breaks away from a primary tumor to lodge in other parts of the body.

"It’s when tumors spread to essential organs, such as the liver or lung, that they become fatal. There is nothing to date that has been approved by the FDA for treatment of cancer that works on that process," said John.

John, who is no longer affiliated with SFVAMC, is currently the president of MandalMed, Inc., a San Francisco-based company working to develop a drug that inhibits metastasis based on these findings. (Jarvis, of SFVAMC/UCSF, has no financial stake in MandalMed.)

A drug that could reduce metastasis would greatly improve upon the beneficial outcomes already achieved with chemotherapy, surgery and radiation, John said. "We’re not trying to develop a cure for cancer. What we’re trying to do is make cancer a disease that one can live with," she said.

As a way of targeting metastasis, John proposed modifying a human protein known as galectin-3, a member of the family of proteins called lectins that bind to sugar molecules on the surfaces of cells. Galectin-3 is known to play multiple roles in cancer formation, including the promotion of cell-to-cell adhesion, or sticking. "The idea was to break that contact and inhibit secondary cancer formation," Jarvis said.

The researchers left the sugar-binding region of galectin-3 intact, but removed the part of the protein that normally allows cells to stick to one another. They then implanted portions of human-derived breast cancer tumors into the chest pads of nude mice, mice having a low-functioning immune system. Once the tumors were established, they injected the experimental animals with truncated galectin-3. The control mice were given sham injections.

By the end of the experiment, the team found that cancer had spread to lymph nodes or other organs in four out of 20 experimental mice versus 11 of 20 control mice. In addition, the post-treatment growth of the implanted tumor fragments was significantly less than in the control animals. Monitoring the animals during this and additional experiments showed that the modified protein did not cause any apparent adverse effects or death in the mice.

Jarvis believes that the modified version of galectin-3 was able to interfere with the breast cancer cells’ ability to stick to one another and to the healthy cells of other organs. "The data supports the hypotheses that truncated galectin-3 inhibits the process of metastasis," he said.

Jarvis and his colleagues at the SFVAMC are currently working on the functional studies that would determine the mechanism behind the reduction in metastasis they observed.

Jarvis said a drug therapy targeting galectin-3 activity might someday be effectively used in combination with currently available cancer medications. "If we can stop metastasis in humans, we will have gone a long way towards successfully treating cancer," he said.

Jarvis and his colleagues at the SFVAMC have since repeated these results and plan to extend the current study by looking at different types of cancer and different truncated versions of galectin-3 in combination with currently available anticancer medications.

Additional authors on the paper include Hakon Leffler, MD, PhD, Barbro Kahl-Knutsson and Inga Svensson of the Institute of Laboratory Medicine at Lund University in Lund, Sweden.

This research was supported by a grant to the Northern California Institute for Research and Education (NCIRE) from the U.S. Department of the Army Breast Cancer Research Program. Based at the SFVAMC, NCIRE is the largest congressionally sanctioned research foundation. The Swedish Medical Research Council also provided support.

Statement of financial disclosure: Neither UCSF, SFVAMC nor Gary Jarvis, PhD, has a financial stake in MandalMed, Inc. Constance John, PhD, serves as president of MandalMed, Inc., but was employed as a research chemist in Jarvis’ laboratory at the time this research was conducted.

Camille Mojica | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>